Case Study: Delivering two prostate cancer trials at scale

0 min

Developing a precision oncology radiopharmaceutical (RPT) is operationally complex, so sponsors must manage risks at every phase of clinical development and execution. Over the past five years, Parexel has completed more than 20 RPT oncology projects for sponsors, involving more than 2,100 patients at over 600 sites in 20 countries. Recently, we helped a biotech company conduct two large, late-stage trials of an RPT imaging agent for prostate cancer. Here is how we did it: